januxrx.com - JANX Income before deduction of interest, taxes and amortization

Graphic logo of Janux Therapeutics Inc (JANX)

What is the status of Janux Therapeutics (JANX) profitability within the precision medicine market? The EBITDA trajectory reflects current dynamics, with the metric currently standing at 0.00. Janux Therapeutics develops T-cell activators for targeted strikes against tumors. Innovative molecules ensure the safety of healthy organs, while global humanitarian protocols completely neutralize any geopolitical risks to the business.

Profit before payment of interest, taxes and amortization: Janux Therapeutics (JANX) for 11/23/2025 - 11/14/2026

Janux Therapeutics Inc - analytical breakdowns and key metrics (JANX)

- market value and analyst target forecast:
Market Price Janux Therapeutics, Inc.|JANX - Consensus Target
- issuer market value details:
Market Value Janux Therapeutics, Inc.|JANX - Enterprise Value
- book capitalization information:
Net Assets per Share Janux Therapeutics|JANX - Company Book Value|Market Cap to Net Assets Ratio januxrx.com|JANX - Aggregate Company Assets
- business debt structure and liquidity details:
Total Debt to Equity Ratio Janux Therapeutics|JANX - Long-Term Debt to Equity Ratio|Short-Term Debt to Capital Janux Corp|JANX - Company Debts|Debt to Book Value Ratio Janux Therapeutics Inc|JANX - Company Long-Term Debt|Short-Term Debt Janux Therapeutics|Critical Liquidity januxrx.com
- company profitability and valuation multiples indicators:
JANX - Net Income|Future Net Profit Janux Therapeutics|JANX - P/E Multiple|Future Price to Earnings Multiple Janux Therapeutics, Inc.|JANX - PEG Multiple|Company Value to EBITDA Janux Therapeutics Inc|JANX - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Janux Therapeutics|JANX - Net earnings per share (EPS TTM)|Quarterly EPS earnings growth januxrx.com|JANX - Earnings per share growth in current year|Net earnings per share change forecast for next year Janux Therapeutics
- sales and revenue data:
JANX - Company Sales|Company Expected Sales Volume januxrx.com|JANX - Price-to-Revenue Ratio|Price to Expected Revenue Ratio Janux Therapeutics, Inc.
Analysis of all company metrics:januxrx.com - JANX
Mass-produced product of Janux Therapeutics, Inc.

Investors use this indicator to assess operational resilience and the business's ability to generate cash flow. The metric captures the daily volume of profit from core operations before depreciation and interest. For Janux Therapeutics (JANX), this reflects the commercialization efficiency of the TRACTIT platform within the precision oncology segment. Actual EBITDA dynamics demonstrate the pace of transition from development to market capture. Analysis based on actual EBITDA allows for the determination of the company's maturity stage.

Competitors of Janux Therapeutics (JANX)

ImmunityBio (IBRX) - Profit before interest, taxes and amortization|IMCR: Operating profit before deduction of amortization|Income before deduction of interest, taxes and amortization RCUS (Arcus Biosciences)|ZYME: Operating profit EBITDA|TNGX - Operating income before deduction of amortization|Profit before payment of interest, taxes and amortization iovance.com|Operating profit before deduction of amortization immatics.com (IMTX)|Profit before payment of interest, taxes and amortization Xencor Inc (XNCR)|Operating profit before deduction of amortization Compass Bio CMPX|Replimune Group Inc - Operating profit before deduction of amortization|Operating profit EBITDA Lyell Pharma LYEL|IPHA - Profit before payment of interest, taxes and amortization|PYXS (Pyxis Oncology) - Operating profit before amortization|cgen.com (CGEN) - Profit before payment of interest, taxes and amortization|Profit before interest, taxes and amortization IO Biotech Corp (IOBT)|Operating profit before deduction of amortization STRO|INKT - Operating profit before depreciation charges|Operating profit before deduction of amortization HOWL (Werewolf Therapeutics)|Company profit before taxes, interest and amortization IMMX|Operating profit EBITDA ALXO (ALX Oncology)|cuebiopharma.com (CUE) - Profit before interest, taxes and amortization|PDS Biotechnology Corp - Operating profit EBITDA|Profit before interest, taxes and amortization Sonnet BioTherapeutics Holdings|MAIA Biotechnology (MAIA) - Profit before payment of interest, taxes and amortization|Liminatus Pharma - Income before deduction of interest, taxes and amortization|LVTX (Lava Tx) - Operating profit EBITDA|Operating profit EBITDA NextCure Inc|Profit before payment of interest, taxes and amortization leaptx.com (LPTX)|INTS: Profit before deduction of interest, taxes, depreciation and amortization|Sensei Biotherapeutics, Inc. - Operating profit before deduction of amortization|Theriva Biologics (TOVX) - Profit before interest, taxes and amortization|gritstonebio.com - Operating profit EBITDA|KA (Kineta) - Operating profit before amortization|NEXI: Operating profit EBITDA|Turnstone Biologics Corporation (TSBX) - Operating profit EBITDA|VCNX (vaccinex.com) - Operating profit EBITDA|HARP: Income before deduction of interest, taxes and amortization